Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost of providing care to those with (a) PANS and (b) PANDAS who have (i) been hospitalised and (ii) left with enduring and life-changing symptoms after receiving in-effective healthcare treatment.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
The Department has made no such estimate as the number of patients affected in this way is currently unknown.
Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of recognising PANS and PANDAS as a condition eligible for personalised NHS treatment.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No assessment has been made.
Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that children and young people living with PANS and PANDAS receive effective, patient-centred care.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
Paediatric Acute-onset Neuropsychiatric Syndrome (PANS) and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
are an emerging area of research and clinical interest for professionals working with children and young people. Should the evidence base develop further, we would look to organisations such as the National Institute for Health and Care Excellence to update clinical policy. NHS England would then consider the development of care pathways for those living with relevant these conditions.
In the meantime, integrated care systems are responsible for planning care for their populations affected by these conditions and healthcare professionals will want to take account of any new research and developments in guidance to ensure that they can continue to provide high quality care to their patients.
Asked by: Jonathan Ashworth (Labour (Co-op) - Leicester South)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent discussions he has had with (a) Cabinet colleagues and (b) stakeholders on the development of care pathways for children and young people living with (i) Paediatric Acute-onset Neuropsychiatric Syndrome (PANS), (ii) Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and (iii) associated immune mediated/post-infective neuro-behavioural disorders.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No such discussions have taken place recently.
Asked by: Luke Evans (Conservative - Bosworth)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he (a) has had and (b) plans to have discussions with NHS England on ensuring the (i) adequacy and (ii) consistency of treatment pathways for children living with (A) PANS and (B) PANDAS; and what steps he is taking to ensure that children living with (1) PANS and (2) PANDAS and their parents receive adequate (x) information and (y) support to take informed decisions on care pathway options.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
No such discussions with NHS England have taken place or are planned at present. Should the evidence base develop further, clinical policy may be updated by relevant organisations such as the National Institute for Health and Care Excellence. NHS England would then consider the development of care pathways for those living with PANS and PANDAS. In the meantime, integrated care systems are responsible for planning care for their populations.
Asked by: Wendy Chamberlain (Liberal Democrat - North East Fife)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the PANS/PANDAS Working Group statement on medical guidelines published 24 February 2023; and whether it is his policy to endorse those guidelines for use in NHS settings.
Answered by Maria Caulfield - Parliamentary Under Secretary of State (Department for Business and Trade) (Minister for Women)
We are aware of the recent guidance published by PANS PANDA UK. No assessment of existing policies against the new guidance has been made currently.